JP7769545B2 - 心不全の治療 - Google Patents

心不全の治療

Info

Publication number
JP7769545B2
JP7769545B2 JP2021547460A JP2021547460A JP7769545B2 JP 7769545 B2 JP7769545 B2 JP 7769545B2 JP 2021547460 A JP2021547460 A JP 2021547460A JP 2021547460 A JP2021547460 A JP 2021547460A JP 7769545 B2 JP7769545 B2 JP 7769545B2
Authority
JP
Japan
Prior art keywords
subject
mitochondria
composition
mitochondrial
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021547460A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519767A5 (https=
JP2022519767A (ja
Inventor
ディー． マッカリー、ジェームズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of JP2022519767A publication Critical patent/JP2022519767A/ja
Publication of JP2022519767A5 publication Critical patent/JP2022519767A5/ja
Priority to JP2025184569A priority Critical patent/JP2026048627A/ja
Application granted granted Critical
Publication of JP7769545B2 publication Critical patent/JP7769545B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
JP2021547460A 2019-02-15 2020-02-14 心不全の治療 Active JP7769545B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025184569A JP2026048627A (ja) 2019-02-15 2025-10-31 心不全の治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962806473P 2019-02-15 2019-02-15
US62/806,473 2019-02-15
PCT/US2020/018371 WO2020168247A1 (en) 2019-02-15 2020-02-14 Treating heart failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025184569A Division JP2026048627A (ja) 2019-02-15 2025-10-31 心不全の治療

Publications (3)

Publication Number Publication Date
JP2022519767A JP2022519767A (ja) 2022-03-24
JP2022519767A5 JP2022519767A5 (https=) 2023-02-22
JP7769545B2 true JP7769545B2 (ja) 2025-11-13

Family

ID=72044848

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021547460A Active JP7769545B2 (ja) 2019-02-15 2020-02-14 心不全の治療
JP2025184569A Pending JP2026048627A (ja) 2019-02-15 2025-10-31 心不全の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025184569A Pending JP2026048627A (ja) 2019-02-15 2025-10-31 心不全の治療

Country Status (7)

Country Link
US (1) US20220160782A1 (https=)
EP (1) EP3923963A4 (https=)
JP (2) JP7769545B2 (https=)
CN (1) CN113710255A (https=)
AU (1) AU2020223358A1 (https=)
CA (1) CA3130213A1 (https=)
WO (1) WO2020168247A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106536056B (zh) 2014-06-13 2021-07-16 儿童医学中心公司 分离线粒体的产品和方法
US11903974B2 (en) * 2015-11-30 2024-02-20 Flagship Pioneering Innovations V, Inc. Methods and compositions relating to chondrisomes from cultured cells
WO2017124037A1 (en) 2016-01-15 2017-07-20 The Children's Medical Center Corporation Therapeutic use of mitochondria and combined mitochondrial agents
WO2025184537A1 (en) * 2024-03-01 2025-09-04 The Board Of Trustees Of The Leland Stanford Junior University Bio-engineered mitochondria for targeted delivery to cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150079193A1 (en) 2012-05-16 2015-03-19 Minovia Therapeutic Ltd. Compositions and methods for inducing angiogenesis
WO2017124037A1 (en) 2016-01-15 2017-07-20 The Children's Medical Center Corporation Therapeutic use of mitochondria and combined mitochondrial agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011757A1 (en) 2005-07-14 2007-01-25 Myogen, Inc. Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart
IL183818A0 (en) 2007-06-10 2007-10-31 Shimon Harpaz Uniformly abrasive confectionery product and process therefor
US20090202606A1 (en) 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
WO2015073396A1 (en) 2013-11-12 2015-05-21 The Brigham And Women's Hospital, Inc. Growth differentiation factor (gdf) for treatment of diastolic heart failure
CN106536056B (zh) 2014-06-13 2021-07-16 儿童医学中心公司 分离线粒体的产品和方法
US11903974B2 (en) 2015-11-30 2024-02-20 Flagship Pioneering Innovations V, Inc. Methods and compositions relating to chondrisomes from cultured cells
JP7218897B2 (ja) 2016-11-16 2023-02-07 ルカ・サイエンス株式会社 心不全の治療及び／又は予防に用いるための心筋幹細胞の製造方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150079193A1 (en) 2012-05-16 2015-03-19 Minovia Therapeutic Ltd. Compositions and methods for inducing angiogenesis
WO2017124037A1 (en) 2016-01-15 2017-07-20 The Children's Medical Center Corporation Therapeutic use of mitochondria and combined mitochondrial agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
左心不全に伴う肺高血圧症の発症メカニズムを解明-新規の心不全治療薬候補の同定-，プレスリリース、東北大学大学院医学系研究科，<URL:https://www.tohoku.ac.jp/japanese/newimg/pressimg/tohokuuniv-press20180710_Shimokawa180703_01web.pdf>
心拡大と心肥大、コラム、東京女子医科大学成人医学センター [オンライン], 2012.06.01 [検索日2023.12.12] ，インターネット:<URL:http://www.twmu.ac.jp/IOG/column/file32.html>
拡張型心筋症、慶應義塾大学病院 KOMPAS [オンライン], 2018.01.26 [検索日2023.12.12]，インターネット:<URL:https://kompas.hosp.keio.ac.jp/contents/000200.html>
肺性心について, メディカルノート [オンライン], 2018.09.11 [検索日2023.12.12]，インターネット:<URL:https://medicalnote.jp/diseases/肺性心>

Also Published As

Publication number Publication date
AU2020223358A1 (en) 2021-09-09
EP3923963A1 (en) 2021-12-22
EP3923963A4 (en) 2022-11-23
WO2020168247A1 (en) 2020-08-20
JP2026048627A (ja) 2026-03-17
JP2022519767A (ja) 2022-03-24
CA3130213A1 (en) 2020-08-20
CN113710255A (zh) 2021-11-26
US20220160782A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
AU2023201193B2 (en) Therapeutic use of mitochondria and combined mitochondrial agents
JP7769545B2 (ja) 心不全の治療
McCully et al. Mitochondrial transplantation: the advance to therapeutic application and molecular modulation
Tang et al. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector
Mao et al. Mesenchymal stem cells overexpressing integrin-linked kinase attenuate left ventricular remodeling and improve cardiac function after myocardial infarction
Mykhaylichenko et al. Experimental induction of reparative morphogenesis and adaptive reserves in the ischemic myocardium using multipotent mesenchymal bone marrow-derived stem cells
WO2020222866A1 (en) Prophylactic and therapeutic use of mitochondria and combined mitochondrial agents
Kanemitsu et al. Insulin-like growth factor-1 enhances the efficacy of myoblast transplantation with its multiple functions in the chronic myocardial infarction rat model
RU2824501C2 (ru) Лечение сердечной недостаточности
Dib et al. Safety and feasibility of percutaneous autologous skeletal myoblast transplantation in the coil-infarcted swine myocardium
Borenstein et al. Non-cultured cell transplantation in an ovine model of non-ischemic heart failure
HK40103035A (en) Therapeutic use of mitochondria and combined mitochondrial agents
HK40103035B (en) Therapeutic use of mitochondria and combined mitochondrial agents
HK40039519A (en) Therapeutic use of mitochondria and combined mitochondrial agents
HK40000946A (en) Therapeutic use of mitochondria and combined mitochondrial agents
HK40000946B (en) Therapeutic use of mitochondria and combined mitochondrial agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230214

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250725

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251001

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251031

R150 Certificate of patent or registration of utility model

Ref document number: 7769545

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150